These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3360157)

  • 1. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics.
    Benckhuijsen C; Kroon BB; van Geel AN; Wieberdink J
    Eur J Surg Oncol; 1988 Apr; 14(2):157-63. PubMed ID: 3360157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of melphalan in isolated perfusion of the limbs.
    Benckhuijsen C; Varossieau FJ; Hart AA; Wieberdink J; Noordhoek J
    J Pharmacol Exp Ther; 1986 May; 237(2):583-8. PubMed ID: 3701643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.
    Thompson JF; Siebert GA; Anissimov YG; Smithers BM; Doubrovsky A; Anderson CD; Roberts MS
    Br J Cancer; 2001 Jul; 85(2):157-65. PubMed ID: 11461070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial.
    Grootenboers MJ; Hendriks JM; van Boven WJ; Knibbe CA; van Putte B; Stockman B; De Bruijn E; Vermorken JB; Van Schil PE; Schramel FM
    J Surg Oncol; 2007 Dec; 96(7):583-9. PubMed ID: 17999399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs?
    Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR; van Dongen JA
    Melanoma Res; 1994 Mar; 4 Suppl 1():13-6. PubMed ID: 8038589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs.
    Kroon BB; Van Geel AN; Benckhuijsen C; Wieberdink J
    Anticancer Res; 1987; 7(3 Pt B):441-2. PubMed ID: 3631900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities.
    Briele HA; Djuric M; Jung DT; Mortell T; Patel MK; Das Gupta TK
    Cancer Res; 1985 Apr; 45(4):1885-9. PubMed ID: 3978649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?
    Wu ZY; Smithers BM; Anderson C; Roberts MS
    Melanoma Res; 2000 Feb; 10(1):47-54. PubMed ID: 10711640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
    Brady MS; Brown K; Patel A; Fisher C; Marx W
    Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique.
    Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M
    Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
    Vahrmeijer AL; van Dierendonck JH; Keizer HJ; Beijnen JH; Tollenaar RA; Pijl ME; Marinelli A; Kuppen PJ; van Bockel JH; Mulder GJ; van de Velde CJ
    Br J Cancer; 2000 May; 82(9):1539-46. PubMed ID: 10789721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
    Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
    Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Melphalan pharmacokinetics during isolated limb regional perfusion in patients with skin melanoma and soft tissue sarcoma].
    Gafton GI; Senchik KY; Petrov VG; V V Semiglazov ; N V Tatyanicheva ; V G Bespalov ; Semiletova YV; Gafton IG; Zinoviev GV; Kireeva GS
    Vopr Onkol; 2015; 61(6):932-6. PubMed ID: 26995981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
    Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
    Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.